Michael A Metzger
CIK 1507220 · Chief Executive Officer · last filed 2026-07-09
Michael A Metzger is a Chief Executive Officer who has filed 65 SEC Form 4 insider transactions across 6 companies since 2010. The most recent filing, for SNDX, was dated Jul 9, 2026. Across all open-market trades the lifetime net is −$16.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SNDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 TOTTEN POND ROAD,
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SNDX | Chief Executive Officer | 517,218 | $13.37 | $6.92M | -$15.40M | 33 | 2026-07-09 |
| PYXS | Director | — | $1.72 | — | $0 | 3 | 2026-03-25 |
| CTI BIOPHARMA CORP (CTIC) Delisted | Director | 4,500 | $9.09 | $40.9K | -$1.20M | 13 | 2023-06-26 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | President & CEO | — | — | — | $0 | 2 | 2015-02-20 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | President and COO | — | — | — | $0 | 1 | 2013-12-20 |
| RESPONSE GENETICS INC (RGDX) Delisted | Director | 1,000 | — | — | $1.5K | 5 | 2012-08-01 |
Recent Filings
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-09 | SNDX | Mixed | — | -$578.2K | EDGAR |
| 2026-07-08 | SNDX | Notice (144) | −32,375 | -$752.4K | EDGAR |
| 2026-06-02 | SNDX | Sell (S) | −6,847 | -$130.0K | EDGAR |
| 2026-06-01 | SNDX | Notice (144) | −6,847 | -$130.0K | EDGAR |
| 2026-03-25 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2026-02-10 | SNDX | Sell (S) | −17,159 | -$360.8K | EDGAR |
| 2026-02-09 | SNDX | Notice (144) | −17,159 | -$360.8K | EDGAR |
| 2026-02-06 | SNDX | Notice (144) | −7,412 | -$152.8K | EDGAR |
| 2026-02-06 | SNDX | Mixed | +210,188 | -$152.8K | EDGAR |
| 2025-09-08 | SNDX | Notice (144) | −157,307 | -$2.68M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.